Ledger Run

Ledger Run

Ledger Run was launched in Tiburon, California by Jeff Bell, a former business development executive at Oracle, who observed that clinical trial payment processes were dominated by manual spreadsheets and fragmented bank transfers. The company serves biotechnology and pharmaceutical firms that need to manage complex site budgets, foreign exchange, and regulatory-compliant payment workflows across dozens of countries. Its founding thesis remains intact: clinical trials are financial operations as much as scientific ones. The platform covers investigator grant management, budget negotiation, site payment automation, and compliance administration. Core buyers are clinical operations and finance teams at mid-to-large biopharma firms. While Ledger Run does not publicly disclose deployment metrics, its technology touches a critical spend category — global clinical trial site payments exceed $40 billion annually (per industry estimates, 2023). Competitors include Greenphire, which was acquired by Coupa, and Oracle's own Siebel Clinical Trial Management System. The company's Atlantic Street Capital investment round in 2020 signaled outside validation of its niche. Ledger Run has maintained a lean profile, operating from a single office in Marin County with a distributed engineering team. As of 2024, the firm had not launched adjacent vehicles or disclosed an investment fund structure. CEO Jeff Bell continues to lead product direction, emphasizing configurability for clinical trial billing rules across jurisdictions. Ledger Run's structural differentiator is its focus on the pre-accounting layer of clinical trials — the budgeting and payment authorization logic that precedes any journal entry. Unlike broader clinical trial management systems that attempt to replace all trial software, Ledger Run integrates with existing CTMS and ERP platforms, positioning itself as a connective layer rather than a rip-and-replace suite.